Co-expression of NMDA-receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic NMDA-receptor-encephalitis: a retrospective clinico-pathology study of 159 patients.
机构:[1]Department of Neurology, West China Hospital, Sichuan University, 37th Guoxuexiang Road, Chengdu, Sichuan Province, China.[2]Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.[3]Department of Neuropathology, University Hospital Erlangen, Erlangen, Germany.[4]Department of Neuropathology, Xuanwu Hospital, Capital Medical University, Beijing, China.医技科室病理科首都医科大学宣武医院
To comprehensively describe the pathological features of neurons in patients with ovarian teratomas and paraneoplastic anti-NMDAR encephalitis (anti-NMDARE), emphasizing on NMDA-receptor expression and infiltrating lymphocytes.
A retrospective study was performed in a large series of 159 patients from the West China Hospital. We retrospectively identified 12 patients with paraneoplastic anti-NMDARE (11 case with ovarian teratomas and 1 case with mixed germ cell tumor), which were compared to 35 patients with teratomas and no encephalitis and to 147 patients with anti-NMDARE and no evidence for tumors. Patient history and outcome were reviewed from the clinical charts and compared between all three groups. Histopathological examination, including double-immunofluorescence of NMDAR subunits and IgG was performed in all teratoma tissues. Magnetic Luminex Assay Human Premixed Multi-Analyte Kit was performed to investigate cytokines profile of CSF.
Patients with paraneoplastic anti-NMDARE had a more severe clinical presentation, i.e. they required more mechanical ventilation and intensive care (p < 0.001). Though immunotherapy was initiated earlier in this group, repeated intravenous immunoglobulin administration (IVIG) was more common (p = 0.002) and with higher cerebrospinal fluid (CSF) antibody titres (p = 0.004). Following tumor resection, the outcome did not differ between groups. A peculiar population of floating-frog like dysplastic neurons were observed only in teratomas of patients with paraneoplastic anti-NMDARE, co-expressing NR1, NR2A, NR2B subunits and IgG. Also, CD20 positive B-cells were more common in anti-NMDARE teratomas. In CSF of paraneoplastic anti-NMDARE patients, TNF-α, IL-10 and GM-CSF concentrations were higher than in negative symptom control and VEGF-A and IL-1a were lower than in anti-NMDARE patients (0.25 < p < 0.05).
Patients with teratomas and paraneoplastic anti-NMDARE revealed a cellular population of dysplastic neurons co-expressing NMDAR subunits, which were the potential source of autoantigens triggering anti-NMDARE. Some inflammatory cytokines may be involved in pathogenesis of paraneoplastic anti-NMDARE.
基金:
This work was supported by grants from National Natural Science
Foundation of China (Grant No. 81571272) and Sichuan province science and
technology project (Grant No. 2019YFH0145).
第一作者机构:[1]Department of Neurology, West China Hospital, Sichuan University, 37th Guoxuexiang Road, Chengdu, Sichuan Province, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Jiang Xin-Yue,Lei Song,Zhang Le,et al.Co-expression of NMDA-receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic NMDA-receptor-encephalitis: a retrospective clinico-pathology study of 159 patients.[J].ACTA NEUROPATHOLOGICA COMMUNICATIONS.2020,8(1):doi:10.1186/s40478-020-00999-2.
APA:
Jiang Xin-Yue,Lei Song,Zhang Le,Liu Xu,Lin Min-Tao...&Li Jin-Mei.(2020).Co-expression of NMDA-receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic NMDA-receptor-encephalitis: a retrospective clinico-pathology study of 159 patients..ACTA NEUROPATHOLOGICA COMMUNICATIONS,8,(1)
MLA:
Jiang Xin-Yue,et al."Co-expression of NMDA-receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic NMDA-receptor-encephalitis: a retrospective clinico-pathology study of 159 patients.".ACTA NEUROPATHOLOGICA COMMUNICATIONS 8..1(2020)